Total debt surged to $86.3M in 2026Q2 from $33.3M one quarter prior while equity flipped to -$16.6M and the current ratio fell to 0.80, rendering debt-to-equity uncomputable and suggesting a materially more constraining capital structure despite $100.1M of cash.
Ocugen, Inc. (OCGN) balance sheet — 14-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 91.43M | 24.34M | 61.68M | 42.97M | 98.49M | 102.65M | 25.88M | 15.77M | 16.4M | 8.18M | 32.08M | 31.24M | 58.86M | 10.35M | 15.08M |
| Cash & Short-Term Investments | 84.26M | 18.57M | 58.51M | 39.46M | 90.93M | 94.96M | 24.04M | 7.44M | 15.54M | 7.98M | 31.91M | 30.91M | 58.06M | 8.73M | 14.72M |
| Cash Only | 24.63M | 18.57M | 58.51M | 39.46M | 77.56M | 94.96M | 24.04M | 7.44M | 15.54M | 7.08M | 31.91M | 30.91M | 58.06M | 8.73M | 14.72M |
| Short-Term Investments | 59.63M | 0 | 0 | 0 | 13.37M | 0 | 0 | 0 | 0 | 900K | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 5.77M | 3.17M | 3.51M | 7.56M | 0 | 0 | 7M | 172K | 122K | 78K | 279K | 729K | 1.13M | 340K |
| Total Non-Current Assets | 16.63M | 19.18M | 20.76M | 21.58M | 10.14M | 3.12M | 1.5M | 1.04M | 1.03M | 2.86M | 4M | 5.55M | 6.64M | 4.45M | 5.96M |
| Property, Plant & Equipment | 12.71M | 14.39M | 16.55M | 17.29M | 6.05M | 1.16M | 633K | 222.46K | 141K | 2.72M | 3.86M | 5.21M | 4.88M | 2.28M | 2.31M |
| Fixed Asset Turnover | 0.35x | 0.31x | 0.24x | 0.35x | 0.41x | - | 0.07x | - | - | - | - | - | - | 0.00x | 0.01x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 510K | 570K | 630K |
| Long-Term Investments | 954K | 0 | 0 | 0 | 0 | 0 | 0 | 151.02K | 150.48K | 137K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.92M | 4.78M | 4.21M | 4.29M | 4.09M | 1.95M | 865K | 667.75K | 736.52K | 0 | 137K | 137K | 604K | 539K | 540K |
| Total Assets | 108.06M | 43.52M | 82.44M | 64.55M | 108.63M | 105.76M | 27.38M | 16.81M | 17.43M | 11.04M | 36.08M | 36.79M | 65.5M | 14.8M | 21.04M |
| Asset Turnover | 0.06x | 0.10x | 0.05x | 0.09x | 0.02x | - | 0.00x | - | - | - | - | - | - | 0.00x | 0.00x |
| Asset Growth % | 161.37% | -47.22% | 27.72% | -40.58% | 2.71% | 286.33% | 62.88% | -3.56% | 57.93% | -69.41% | -1.92% | -43.84% | 342.68% | -29.69% | - |
| Total Current Liabilities | 118.9M | 23.04M | 21.59M | 17.09M | 28.53M | 7M | 3.61M | 4.54M | 2.87M | 3.81M | 5.17M | 6.36M | 8.25M | 5.09M | 4.4M |
| Accounts Payable | 5.07M | 6.2M | 4.24M | 3.17M | 8.06M | 2.31M | 395K | 1.9M | 1.59M | 776K | 1.95M | 2.25M | 4.89M | 2.53M | 1.04M |
| Days Payables Outstanding | 3.27K | 947.56 | 786.94 | 1.64K | - | - | 22.69 | 85.57 | 11.7K | 184.64 | 425 | 509.51 | - | - | - |
| Short-Term Debt | 83.15M | 1.25M | 1.33M | 0 | 0 | 0 | 234K | 0 | 0 | 178K | 583K | 583K | 405K | 0 | 0 |
| Deferred Revenue (Current) | 17.71M | 5.91M | 8.37M | 10.53M | 11.22M | 0 | 0 | 2.27M | 10M | 2.02M | 2.13M | 2.98M | 2.83M | 0 | 0 |
| Other Current Liabilities | 22.26M | 6.69M | 5.25M | 1.03M | 3.11M | 1.72M | 1.68M | -2.06M | 948K | 1.18M | 1.24M | 2.77M | 2.22M | 1.69M | 1.14M |
| Current Ratio | 0.77x | 1.06x | 2.86x | 2.51x | 3.45x | 14.66x | 7.16x | 3.47x | 5.71x | 2.15x | 6.20x | 4.91x | 7.13x | 2.03x | 3.42x |
| Quick Ratio | 0.77x | 1.06x | 2.86x | 2.51x | 3.45x | 14.66x | 7.16x | 3.47x | 5.71x | 2.15x | 6.20x | 4.91x | 7.13x | 2.03x | 3.42x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.84M | 32.64M | 31.22M | 6.89M | 6.12M | 2.94M | 2.21M | 1.25M | 15.01M | 18.5M | 17.34M | 2.23M | 3.04M | 85.26M | 36.35M |
| Long-Term Debt | 1.74M | 27.54M | 27.34M | 2.8M | 2.29M | 1.71M | 1.82M | 1.07M | 1.02M | 0 | 178K | 761K | 1.34M | 0 | 0 |
| Capital Lease Obligations | 12.61M | 3.49M | 3.31M | 3.57M | 3.59M | 1.23M | 389K | 163.2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 773K | 0 | 0 | 918K | 0 | 0 | 0 | 0 | -1.02M | 0 | 0 | 0 | 651K | 0 | 0 |
| Other Non-Current Liabilities | 2.28M | 1.6M | 564K | 527K | 244K | 0 | 0 | 9.76K | 4M | 18.5M | 17.16M | 1.47M | 1.05M | 85.26M | 36.35M |
| Total Liabilities | 125.74M | 55.68M | 52.81M | 23.98M | 34.65M | 9.94M | 5.83M | 5.79M | 17.89M | 22.3M | 22.51M | 8.59M | 11.29M | 90.35M | 40.76M |
| Total Debt | 88.56M | 33.14M | 32.5M | 6.94M | 6.37M | 3.31M | 2.49M | 1.41M | 238K | 178K | 761K | 1.34M | 1.75M | 0 | 0 |
| Net Debt | 63.93M | 14.57M | -26.01M | -32.52M | -71.19M | -91.65M | -21.55M | -6.04M | -15.3M | -6.9M | -31.15M | -29.57M | -56.31M | -8.73M | -14.72M |
| Debt / Equity | -5.01x | - | 1.10x | 0.17x | 0.09x | 0.03x | 0.12x | 0.13x | - | - | 0.06x | 0.05x | 0.03x | - | - |
| Debt / EBITDA | -1.33x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.96x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -7.03x | -12.08x | - | - | - | -738.46x | -19.81x | -8.01x | -88.77x | -197.12x | -217.47x | -239.78x | -149.95x | - | -18.76x |
| Total Equity | -17.68M | -12.17M | 29.63M | 40.56M | 73.98M | 95.82M | 21.55M | 11.02M | -458K | -11.27M | 13.57M | 28.2M | 54.21M | -75.55M | -19.71M |
| Equity Growth % | -1447.5% | -141.06% | -26.95% | -45.17% | -22.79% | 344.63% | 95.58% | 2505.77% | 95.94% | -183.05% | -51.89% | -47.98% | 171.74% | -283.31% | - |
| Book Value per Share | -0.05 | -0.04 | 0.11 | 0.17 | 0.34 | 0.49 | 0.19 | 0.79 | -0.74 | -29.82 | 56.57 | 127.87 | 2120.07 | -355.35 | -92.71 |
| Total Shareholders' Equity | -17.68M | -12.17M | 29.63M | 40.56M | 73.98M | 95.82M | 21.55M | 11.02M | -458K | -11.27M | 13.57M | 28.2M | 54.21M | -75.55M | -19.71M |
| Common Stock | 3.39M | 3.13M | 2.92M | 2.57M | 2.22M | 2M | 1.84M | 527.47K | 513K | 159K | 159K | 132K | 127K | 6K | 6K |
| Retained Earnings | -455.72M | -408.07M | -340.22M | -286.17M | -223.09M | -131.67M | -73.3M | -51.48M | -216.83M | -208.19M | -181.77M | -165.56M | -133.54M | -110.75M | -85.04M |
| Treasury Stock | -48K | -48K | -48K | -48K | -48K | -48K | -48K | -47.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 146K | 61K | 48K | 20K | 26K | 0 | 0 | 0 | -10.29M | -10.92M | -9.39M | -7.99M | -6.38M | -5.65M | -5.15M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying OCGN stock.
As of 2025, Ocugen, Inc. (OCGN) had total assets of $43.5M including $24.3M in current assets.
Ocugen, Inc. (OCGN) carries total debt of $33.1M, offset by $18.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Ocugen, Inc. (OCGN) has total shareholders' equity (book value) of $-12.2M ($-0.04 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Ocugen, Inc. (OCGN) reported a current ratio of 1.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Negative equity amid rising leverage
Metrics are mathematically derived from official filings.
Asset Growth Masks Equity Erosion
Ocugen's total assets climbed to $124.2M in 2026Q2 from $51.8M in early 2024 according to its quarterly balance sheets, yet equity flipped to -$16.6M as liabilities exceeded assets, suggesting balance sheet expansion driven by leverage rather than retained value creation.
The balance sheet's size has more than doubled over ten quarters, yet the expansion appears concentrated in a single quarter — total debt rose from $33.3M to $86.3M between 2026Q1 and 2026Q2 while equity fell from $5.8M to -$16.6M. With accumulated losses deepening to -$452.1M and book value now negative, this pattern suggests the company's financial structure has shifted materially toward creditor claims, which may constrain strategic flexibility and refinancing options.
Debt Surge Reshapes Capital Structure
Total debt rose sharply to $86.3M in 2026Q2 from $33.3M in the prior quarter, as disclosed in Ocugen's filings, while negative equity of -$16.6M renders the debt-to-equity ratio uncomputable — a shift suggesting leverage has moved from moderate to potentially constraining.
Debt had been stable near $33M for five consecutive quarters before the 2026Q2 spike, implying a discrete financing event rather than gradual accumulation. At $86.3M, debt now represents roughly 69% of total assets — a sharp concentration of creditor claims on a balance sheet that simultaneously shows negative book equity. Investors should monitor whether servicing costs associated with this step-change in borrowing will compound the operating losses already evident in recent income statements.
Cash Strength Contradicts Sub-1.0 Ratio
Ocugen's current ratio fell to 0.80 in 2026Q2 — the first sub-1.0 reading in ten quarters — while cash climbed to $100.1M, based on reported balance sheets, suggesting short-term obligations may now outpace liquid assets despite a substantial cash balance.
The juxtaposition of a record-high cash position against a deteriorating current ratio implies that non-cash current liabilities have expanded materially alongside the debt raise rather than being extinguished by the inflow. The ratio had historically ranged between 1.04 and 2.86, so the drop to 0.80 marks a structural break that may indicate reclassification of debt into current maturities or a surge in accrued obligations. With $100.1M of cash against $140.8M of total liabilities, the theoretical buffer exists, but its availability for near-term claims depends on the composition of those obligations, which warrants further investigation.
Book Value Exhausted by Cumulative Losses
Ocugen's equity deteriorated from $30.3M in 2024Q1 to -$16.6M in 2026Q2, driven by accumulated retained losses of -$452.1M, as reported in its financial statements — indicating cumulative losses and recent leverage have fully eroded the shareholders' book value position.
The equity line has been volatile — swinging from $40.6M in 2024Q3 to $3.1M a year later — but the trajectory is unambiguously downward, with retained losses widening by roughly $12M to $25M per quarter across the window. Negative book value means the company's assets are now entirely claims of creditors and other liabilities, a condition that typically raises the cost of future equity issuance. Given that the income statement already shows deepening losses without a corresponding revenue inflection, the equity erosion appears structural rather than a timing artifact.
Cash Inflow May Be Debt-Encumbered
Ocugen's cash jumped from $31.9M to $100.1M in a single quarter alongside a $53.0M debt increase, per its balance sheets — yet the current ratio simultaneously fell to 0.80, suggesting the new liquidity may already be encumbered by near-term obligations warranting investigation.
A casual reading might celebrate the roughly $68M cash build as balance sheet strengthening, but the concurrent deterioration of equity and current ratio suggests the inflow arrived alongside offsetting obligations rather than representing free cash generation. Deferred revenue also fell to $0 in 2026Q2 from $5.2M the prior quarter, eliminating what had been a modest non-debt source of working capital. The combination of a debt-funded cash pile, vanishing deferred revenue, and negative book equity points to a liquidity position that may be more fragile than the headline cash figure implies.